Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cutisanol Gel is a topical dermatological combination product developed by the Brazilian pharmaceutical company Millet Roux. It contains bismuth subgallate (1.5 mg/g) and zinc oxide (45 mg/g) as its active ingredients. The formulation is specifically indicated for the prevention and treatment of diaper rash, heat rash (miliaria), skin irritations such as chafing, and solar erythema (sunburn). It functions through a protective and antiseptic mechanism, creating a physical barrier on the skin that shields it from contact with irritants like urine and feces while providing emollient, moisturizing, and soothing effects. Approved for both adult and pediatric use, Cutisanol Gel has been marketed in Brazil since 1940.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cutisanol Gel.